MolecuLight Announces Formal ITC Investigation
MolecuLight has shared exciting news regarding the United States International Trade Commission's (ITC) decision to begin an investigation. This action comes in response to a complaint that MolecuLight Corp and MolecuLight Inc previously filed, focusing on the SnapshotGLO product.
The Investigation's Focus
The ITC will be examining whether the SnapshotGLO product infringes upon U.S. Patent No. 10,438,356, currently held by University Health Network and exclusively licensed to MolecuLight. The investigation aims to determine if the import and sale of SnapshotGLO in the United States violate U.S. trade laws.
Respondents and Remedies Sought
The respondents in this critical investigation include Kent Imaging Inc., based in Canada, and Adiuvo Diagnostics Pvt. Ltd. from India. MolecuLight's complaint outlines their requests to stop the importation of any infringing products into the United States and to cease their sales in the U.S. market. This strong action is intended to protect their innovations and maintain a fair marketplace.
Timeline and Legal Proceedings
The ITC formally voted to initiate this investigation on January 28, 2026, and has assigned the matter to an administrative law judge, ensuring a thorough legal review of all presented evidence and arguments.
CEO's Statement on the Investigation
Anil Amlani, the CEO of MolecuLight, expressed confidence and optimism regarding the ITC's decision. He stated, "We are pleased that the ITC has voted to institute this investigation. This action advances the process we initiated with our complaint and provides a formal forum to address the issues we raised concerning the unlawful importation of infringing products."
About MolecuLight
MolecuLight is a privately held medical imaging company with a global reach. It focuses on manufacturing and commercializing innovative medical imaging devices such as the MolecuLight i:X® and DX® for wound imaging. Both systems are FDA-cleared Class II point-of-care solutions that provide real-time detection of elevated bacterial burden and accurate digital measurements of wounds. Additionally, the MolecuLight DX® incorporates thermal imaging capabilities for comprehensive wound assessment. The clinical utility and effectiveness of these technologies are supported by more than 100 peer-reviewed publications, affirming their significance in advancing wound care solutions.
Frequently Asked Questions
What is the ITC investigation about?
The ITC investigation revolves around allegations of patent infringement related to the SnapshotGLO product by MolecuLight.
Who are the respondents in this investigation?
The respondents are Kent Imaging Inc. and Adiuvo Diagnostics Pvt. Ltd.
What patent is being investigated?
The investigation concerns U.S. Patent No. 10,438,356, which is owned by University Health Network and licensed to MolecuLight.
What does MolecuLight hope to achieve through this investigation?
MolecuLight seeks remedies to prevent the importation and sale of infringing products in the United States.
What technologies does MolecuLight offer?
MolecuLight offers the MolecuLight i:X® and DX® imaging devices for real-time bacterial detection and wound assessment.
